Flash monitoring is a clinically effective method for achieving compensation for diabetes mellitus type 1


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Introduction. Continuous glucose monitoring (CGM) is currently one of the most promising methods for controlling type 1 diabetes (T1D). Flash monitoring is the most relevant and promising direction in diabetology, which allows to monitor the level of glycemia an unlimited number of times and, as well as does not require calibration of the device. The aim of the study: to evaluate the clinical and metabolic effectiveness of flash monitoring of glycemia in patients with T1D. Methods. The study included 80 patients with T1D on various insulin therapy regimens. All patients were tested for glycated hemoglobin (HbA1c), flash glycemia monitoring, and quality of life assessment using the MOS SF 36 and PedsQl Diabetic module 3.2 questionnaires. Based on the glycemic charts were evaluated: the average level of glycemia (mmol/l), time of blood glucose above target value (%), time of glucose within target values (time in range), time of blood glucose below target values (%), frequency of Hypo - and hyperglycemia (episodes per week), the average daily dose of insulin (U/l). Results. HbA1c decreased by 1.6% (p<0.001) at the end of the study in the pump insulin therapy group. In patients of the basic bolus group HbA1c decreased by 0.6% and reached 8.9 % (p=0.028). When comparing the glycemic control indicators of the two groups, the average blood glucose level decreased in the pump insulin therapy group to 7.51+1.53 mmol/l, in the second group this indicator was 7.25+2.43 mmol /1 (p<0.001). When assessing the quality of life indicators, improvement was found in both the first and second groups. Conclusion. Continuous monitoring, including flash monitoring, is an effective method of monitoring and achieving glycemic goals in patients with T1D, and is also an optimal tool for improving the quality of life regardless of the insulin therapy regimen.

全文:

受限制的访问

作者简介

Y. Samoilova

Siberian State Medical University

Moskovsky trakT., 2, Tomsk, 634050, Russian Federation

M. Koshmeleva

Siberian State Medical University

Moskovsky trakT., 2, Tomsk, 634050, Russian Federation

O. Oleynik

Siberian State Medical University

Moskovsky trakT., 2, Tomsk, 634050, Russian Federation

T. Filippova

Siberian State Medical University

Moskovsky trakT., 2, Tomsk, 634050, Russian Federation

I. Tolmachev

Siberian State Medical University

Moskovsky trakT., 2, Tomsk, 634050, Russian Federation

D. Kudlay

NRC Institute of Immunology FMBA of Russia; I.M. Sechenov First Moscow State Medical University

Kashirskoye highway, 24, Moscow, 115522, Russian Federation; Trubetskaya streeT., 8, bldg. 2, Moscow, 119991, Russian Federation

V. Mutalimi

Siberian State Medical University

Moskovsky trakT., 2, Tomsk, 634050, Russian Federation

N. Bolotova

Saratov State Medical University named after V.I. Razumovsky

Email: mvbulavko@mail.ru
Bolshaya Kazachia streeT., 112, Saratov, 410012, Russian Federation

参考

  1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352 (9131): 837-53. https://doi.org/10.1016/S0140-6736(98)07019-6
  2. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., Raskin P., Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 2005; 353 (25): 2643-53. https://doi.org/10.1056/NEJMoa052187
  3. Orchard T.J., Nathan D.M., Zinman B., Cleary P., Brillon D., Backlund J.Y., Lachin J.M. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015; (1): 45-53. https://doi.org/10.1001/jama.2014.16107.
  4. Самойлова Ю.Г, Ротканк М.А., Жукова Н.Г, Матвеева М.В., Толмачев И.В., Кудлай Д.А. Вариабельность гликемии у пациентов с сахарным диабетом 1-го типа: связь с когнитивной дисфункцией и данными магнитно-резонансных методов исследования. Проблемы Эндокринологии. 2018; 64 (5): 286-91.
  5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: клинические рекомендации. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. Сахарный диабет. 2017; 20 (1S, вып. 8): 1-121.
  6. Самойлова Ю.Г., Ротканк М.А., Жукова Н.Г., Матвеева М.В., Толмачев И.В., Кудлай Д.А. Маркеры когнитивных нарушений и вариабельность гликемии у пациентов с сахарным диабетом 1-го типа. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018; 118 (4): 48-51.
  7. Самойлова Ю.Г., Ротканк М.А., Жукова H. Г., Матвеева М.В., Толмачев И.В., Тонких O. С., Кудлай Д.А. Применение магнитнорезонансных методов исследования головного мозга у пациентов с сахарным диабетом 1-го типа и когнитивной дисфункцией. Неврологический журнал. 2018; 23 (2): 86-92.
  8. Davis W.A., Davis T.M. Cardiovascular risk prediction in adults with type 1 diabetes: the Fremantle Diabetes Study Diabetes Res. Clin. Pract. 2010; 90: 75-8.
  9. Dean J. Organising care for people with diabetes and renal disease. J. Ren. Care. 2012; 38 (1): 23-9.
  10. Eeg-Olofsson K., Cederholm J., Nilsson P.M. et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes: an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care. 2010; 33: 1640-6.
  11. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2017; 40 (1): 1-135.
  12. Кошмелева М.В., Ю.Г Самойлова, О.С. Кобякова, Д.А. Кудлай, О.А. Олейник, М.В. Матвеева, Т.А. Филиппова, И.В Толмачев Опыт применения технологий дистанционного мониторинга сахарного диабета 1-го типа на этапе амбулаторного звена здравоохранения Педиатрия. 2019; 98 (5): 219-24.
  13. Raccah D., Sulmont V., Reznik Y. et al. In?cremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: The Real Trend study. Diabetes Care. 2009; 32 (12): 2245-50.
  14. Bolinder J., Antuna R., Geelhoed-Duijvestijn P. et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016; 388 (10057): 2254-63.
  15. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring (JDRF-CGM) trial. Diabetes Care. 2010; 33: 17-22.
  16. Battelino T., Conget I., Olsen B. et al. SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012; 55: 3155-62.
  17. Riveline J.P., Schaepelynck P., Chaillous L. et al. EVADIAC Sensor Study Group. Assessment of patient-led or physician-driven continuous glucose monitoring in patients with poorly controlled type 1 diabetes using basal-bolus insulin regimens: a 1-year multicenter study Diabetes Care. 2012; 35: 965-71.
  18. Skyler J.S. Diabetic complications. The importance of glucose control. Endocrinol. Metab. Clin. North Am. 1996; 25 (2): 243-54.
  19. Ware J.E., Kosinski M., Keller S.D. SF-36 physical and mental health summary scales: a user's manual. New England Medical Center Hospital; Health Institute. 5-th print. Boston, 1994.
  20. Varni J., Seid M., Kurtin P. The PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med. Care. 2001; 39: 800-12.
  21. Никитина Т.П., Киштович А.В., Моисеенко Е.И. и др. Исследование качества жизни в педиатрии: разработка русской версии опросника PedsQL 4.0 Generic Core Scales для оценки качества жизни детей 8-12 лет. Вестник Межнационального центра исследования качества жизни. 2003; 1: 35-44.
  22. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range, Tadej Battelino, Diabetes Care. 2019; 42 (8): 1593-603. https://doi.org/10.2337/dci19-0028
  23. Pickup J., Mattock M., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials. BMJ. 2002; 324 (7339): 705.
  24. Шестакова М.В., Майоров А.Ю., Филиппов Ю.И. и др. Федеральные клинические рекомендации по помповой инсулинотерапии и непрерывному мониторированию гликемии у больных сахарным диабетом. Проект. Проблемы эндокринологии. 2015; 61 (6): 55-78.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2020
##common.cookie##